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EDITORIAL COMMENT 
 
Modern medicine aspires to achieve personalized treatment in which diagnostic investigations and 
therapy are tailored toward the individual patient. In patients with nephrolithiasis this approach is 
more than ideological since uncovering the underlying genetic mutation can distinctly change the 
treatment strategy. For example, restricting tanning bed use for a patient with identified CYP24A1 
mutation is highly specific1 and is distinct from genericstone prevention advice focusing on fluid 
intake. 
In this timely review the authors summarize known and suspected molecular genetic players that 
may underlie monogenic nephrolithiasis, which isestimated to affect 2% of adult stone formers. 
While the heritability of renal stones is well established, the group of patients with calcium 
containing renal stones labelled as having idiopathic nephrolithiasis remains enigmatic.2 
Next generation sequencing approaches haveallowed significant percentages of cases in selected 
cohorts to be “solved” through identification of an underlying monogenic genetic disorder 
predisposing to renal stone formation. This genetic information allows preventive medical therapies 
to be personalized, truly prioritizing stone prevention over stone removal and avoiding problems 
associated with delayed diagnosis, such as disease recurrence in transplant recipients of kidneys 
with undiagnosed adenine phosphoribosyltransferase deficiency. The question that remains 
concerns the depth of investigation needed. Molecular genetic testing is becoming more accessible 
and cheaper but does not replace careful metabolic examination and evaluation of urine 
biochemistry. The true role for personalized approaches is precise phenotyping of every recurrent 
stone former, allowing targeted genotyping to be performed and understood in its correct context. 
The authors hint that the future of understanding renal stone disease will rely more on genetic 
testing, and they provide a pertinent reference point for the use of such tests. 
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